Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFbCDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)

Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFbCDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)

PTEFbCDK9 mediated transcription of short-lived anti-apoptotic survival proteins like Mcl-1 and Myc, plays a critical role in cancer cell growth and survival in various tumor entities including AML. In addition, these survival proteins exhibit important functions in the development of resistance to...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 2016-07, Vol.76 (14_Supplement), p.3022-3022
Hauptverfasser: Scholz, Arne, Oellerich, Thomas, Hussain, Akhtar, Lindner, Sarah, Luecking, Ulrich, Walter, Annette O, Ellinghaus, Peter, Valencia, Ray, von Nussbaum, Franz, Mumberg, Dominik, Brands, Michael, Ince, Stuart, Serve, Hubert, Ziegelbauer, Karl
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3022
container_issue 14_Supplement
container_start_page 3022
container_title Cancer research (Chicago, Ill.)
container_volume 76
creator Scholz, Arne
Oellerich, Thomas
Hussain, Akhtar
Lindner, Sarah
Luecking, Ulrich
Walter, Annette O
Ellinghaus, Peter
Valencia, Ray
von Nussbaum, Franz
Mumberg, Dominik
Brands, Michael
Ince, Stuart
Serve, Hubert
Ziegelbauer, Karl
description PTEFbCDK9 mediated transcription of short-lived anti-apoptotic survival proteins like Mcl-1 and Myc, plays a critical role in cancer cell growth and survival in various tumor entities including AML. In addition, these survival proteins exhibit important functions in the development of resistance to chemotherapy.
doi_str_mv 10.1158/1538-7445.AM2016-3022
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_1846403776</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1846403776</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_18464037763</originalsourceid><addsrcrecordid>eNqVjc1OwzAQhC0EEuXnEZD2WKSm2PlpArdQWoGgUg-9cKocd9ssOHaxnaI-Ly9CihB3TqPdmW-GsSvBh0JkxY3IkiLK0zQblrOYi1GU8Dg-Yr2__zHrcc6LKEvz-JSdef_WnZngWY99lZUPTqoAB-gO7stXECJNsjwegIQ1OR8iMpHS0vsB1LSp9R48alSBdjiArQ1oAkizAuuk7ky5k6RlpRHI1FRRsA7sGuaLybQaPzzfgmqd65guSgbmtfQITwPwtf30oKzZkVFkNl1loCi0TYfLwxiFH2DrUGkypKSGxq5Q-0O7VG1AaPaoLa1AY_uODUnol7OX6wt2spba4-WvnrP-dLIYP0ZbZz9a9GHZkFeotTRoW78URTpKeZLno-Qf0W8EC3xP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1846403776</pqid></control><display><type>article</type><title>Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFbCDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><creator>Scholz, Arne ; Oellerich, Thomas ; Hussain, Akhtar ; Lindner, Sarah ; Luecking, Ulrich ; Walter, Annette O ; Ellinghaus, Peter ; Valencia, Ray ; von Nussbaum, Franz ; Mumberg, Dominik ; Brands, Michael ; Ince, Stuart ; Serve, Hubert ; Ziegelbauer, Karl</creator><creatorcontrib>Scholz, Arne ; Oellerich, Thomas ; Hussain, Akhtar ; Lindner, Sarah ; Luecking, Ulrich ; Walter, Annette O ; Ellinghaus, Peter ; Valencia, Ray ; von Nussbaum, Franz ; Mumberg, Dominik ; Brands, Michael ; Ince, Stuart ; Serve, Hubert ; Ziegelbauer, Karl</creatorcontrib><description>PTEFbCDK9 mediated transcription of short-lived anti-apoptotic survival proteins like Mcl-1 and Myc, plays a critical role in cancer cell growth and survival in various tumor entities including AML. In addition, these survival proteins exhibit important functions in the development of resistance to chemotherapy.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>DOI: 10.1158/1538-7445.AM2016-3022</identifier><language>eng</language><ispartof>Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3022-3022</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids></links><search><creatorcontrib>Scholz, Arne</creatorcontrib><creatorcontrib>Oellerich, Thomas</creatorcontrib><creatorcontrib>Hussain, Akhtar</creatorcontrib><creatorcontrib>Lindner, Sarah</creatorcontrib><creatorcontrib>Luecking, Ulrich</creatorcontrib><creatorcontrib>Walter, Annette O</creatorcontrib><creatorcontrib>Ellinghaus, Peter</creatorcontrib><creatorcontrib>Valencia, Ray</creatorcontrib><creatorcontrib>von Nussbaum, Franz</creatorcontrib><creatorcontrib>Mumberg, Dominik</creatorcontrib><creatorcontrib>Brands, Michael</creatorcontrib><creatorcontrib>Ince, Stuart</creatorcontrib><creatorcontrib>Serve, Hubert</creatorcontrib><creatorcontrib>Ziegelbauer, Karl</creatorcontrib><title>Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFbCDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)</title><title>Cancer research (Chicago, Ill.)</title><description>PTEFbCDK9 mediated transcription of short-lived anti-apoptotic survival proteins like Mcl-1 and Myc, plays a critical role in cancer cell growth and survival in various tumor entities including AML. In addition, these survival proteins exhibit important functions in the development of resistance to chemotherapy.</description><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqVjc1OwzAQhC0EEuXnEZD2WKSm2PlpArdQWoGgUg-9cKocd9ssOHaxnaI-Ly9CihB3TqPdmW-GsSvBh0JkxY3IkiLK0zQblrOYi1GU8Dg-Yr2__zHrcc6LKEvz-JSdef_WnZngWY99lZUPTqoAB-gO7stXECJNsjwegIQ1OR8iMpHS0vsB1LSp9R48alSBdjiArQ1oAkizAuuk7ky5k6RlpRHI1FRRsA7sGuaLybQaPzzfgmqd65guSgbmtfQITwPwtf30oKzZkVFkNl1loCi0TYfLwxiFH2DrUGkypKSGxq5Q-0O7VG1AaPaoLa1AY_uODUnol7OX6wt2spba4-WvnrP-dLIYP0ZbZz9a9GHZkFeotTRoW78URTpKeZLno-Qf0W8EC3xP</recordid><startdate>20160715</startdate><enddate>20160715</enddate><creator>Scholz, Arne</creator><creator>Oellerich, Thomas</creator><creator>Hussain, Akhtar</creator><creator>Lindner, Sarah</creator><creator>Luecking, Ulrich</creator><creator>Walter, Annette O</creator><creator>Ellinghaus, Peter</creator><creator>Valencia, Ray</creator><creator>von Nussbaum, Franz</creator><creator>Mumberg, Dominik</creator><creator>Brands, Michael</creator><creator>Ince, Stuart</creator><creator>Serve, Hubert</creator><creator>Ziegelbauer, Karl</creator><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20160715</creationdate><title>Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFbCDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)</title><author>Scholz, Arne ; Oellerich, Thomas ; Hussain, Akhtar ; Lindner, Sarah ; Luecking, Ulrich ; Walter, Annette O ; Ellinghaus, Peter ; Valencia, Ray ; von Nussbaum, Franz ; Mumberg, Dominik ; Brands, Michael ; Ince, Stuart ; Serve, Hubert ; Ziegelbauer, Karl</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_18464037763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scholz, Arne</creatorcontrib><creatorcontrib>Oellerich, Thomas</creatorcontrib><creatorcontrib>Hussain, Akhtar</creatorcontrib><creatorcontrib>Lindner, Sarah</creatorcontrib><creatorcontrib>Luecking, Ulrich</creatorcontrib><creatorcontrib>Walter, Annette O</creatorcontrib><creatorcontrib>Ellinghaus, Peter</creatorcontrib><creatorcontrib>Valencia, Ray</creatorcontrib><creatorcontrib>von Nussbaum, Franz</creatorcontrib><creatorcontrib>Mumberg, Dominik</creatorcontrib><creatorcontrib>Brands, Michael</creatorcontrib><creatorcontrib>Ince, Stuart</creatorcontrib><creatorcontrib>Serve, Hubert</creatorcontrib><creatorcontrib>Ziegelbauer, Karl</creatorcontrib><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scholz, Arne</au><au>Oellerich, Thomas</au><au>Hussain, Akhtar</au><au>Lindner, Sarah</au><au>Luecking, Ulrich</au><au>Walter, Annette O</au><au>Ellinghaus, Peter</au><au>Valencia, Ray</au><au>von Nussbaum, Franz</au><au>Mumberg, Dominik</au><au>Brands, Michael</au><au>Ince, Stuart</au><au>Serve, Hubert</au><au>Ziegelbauer, Karl</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFbCDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><date>2016-07-15</date><risdate>2016</risdate><volume>76</volume><issue>14_Supplement</issue><spage>3022</spage><epage>3022</epage><pages>3022-3022</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><abstract>PTEFbCDK9 mediated transcription of short-lived anti-apoptotic survival proteins like Mcl-1 and Myc, plays a critical role in cancer cell growth and survival in various tumor entities including AML. In addition, these survival proteins exhibit important functions in the development of resistance to chemotherapy.</abstract><doi>10.1158/1538-7445.AM2016-3022</doi></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3022-3022
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_1846403776
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research
title Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFbCDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T00%3A07%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Abstract%203022:%20BAY%201143572,%20a%20first-in-class,%20highly%20selective,%20potent%20and%20orally%20available%20inhibitor%20of%20PTEFbCDK9%20currently%20in%20Phase%20I,%20shows%20convincing%20anti-tumor%20activity%20in%20preclinical%20models%20of%20acute%20myeloid%20leukemia%20(AML)&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=Scholz,%20Arne&rft.date=2016-07-15&rft.volume=76&rft.issue=14_Supplement&rft.spage=3022&rft.epage=3022&rft.pages=3022-3022&rft.issn=0008-5472&rft.eissn=1538-7445&rft_id=info:doi/10.1158/1538-7445.AM2016-3022&rft_dat=%3Cproquest%3E1846403776%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1846403776&rft_id=info:pmid/&rfr_iscdi=true